Statin-fibrate combination therapy for hyperlipidaemia: a review

@article{Wierzbicki2003StatinfibrateCT,
  title={Statin-fibrate combination therapy for hyperlipidaemia: a review},
  author={Anthony S. Wierzbicki and Dr. D. P. Mikhailidis and Richard Wray and Michael Schachter and Robert Cramb and William Simpson and Claire Byrne},
  journal={Current Medical Research and Opinion},
  year={2003},
  volume={19},
  pages={155 - 168}
}
SUMMARY Statins and fibrates are well-established treatments for hyperlipidaemias and the prevention of vascular events. However, fibrate + statin therapy has been restricted following early reports of rhabdomyolysis that mainly involved gemfibrozil, originally with lovastatin, and recently, with cerivastatin. Despite this limitation, several reports describing combination therapy have been published. This review considers these studies and the relevant indications and contraindications. Statin… Expand
Statin-fibrat kombinasyon tedavisi
TLDR
The role of combined statin-fibrate therapy in dyslipidemia, their mechanisms of action, efficacy and safety, and precautions needed to be taken to reduce side effects are reviewed in the light of literature. Expand
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins
TLDR
This is the largest phase III randomized, controlled clinical programme to date evaluating the efficacy and safety of the combined use of a new formulation of fenofibric acid with three commonly prescribed statins in patients with mixed dyslipidaemia. Expand
Statin–fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low
TLDR
Improved outcomes with combination therapy were related to younger age, no previous CVD and improvements in non-HDL-C and TG levels, and statin–fibrate combinations should still be considered in appropriate patients and not be neglected based on misinterpretation of the current evidence base. Expand
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
TLDR
For patients who do not reach their cholesterol goal with a statin, adding ezetimibe 10 mg significantly reduces LDL‐C compared with statin monotherapy, and this treatment option may help patients reach the new ‘stricter’ cholesterol goals. Expand
Fibrates: Risk Benefits and Role in Treating Dyslipidemias
TLDR
Fibrates have an important role in individualized approaches to management of patients at high risk of cardiovascular disease with mixed dyslipidemia and while the overall risk reduction may be moderate compared to statin therapy, a substantially greater magnitude of benefit may exist in this subset of patients. Expand
Fibrates: where are we now?
TLDR
Combination fibrates, statins, and combined therapy can be more effective in achieving optimal lipid levels than just fibrate or statin therapy alone without significant side effects as long as gemfibrozil is not used in therapy. Expand
Review: Fibrates: therapeutic review
TLDR
Clinical evidence has demonstrated the value of fibrate therapy in secondary and primary prevention settings, as well as in patients with type 2 diabetes, however, FIELD, the largest fibrates study to date in diabetic patients, showed a non-s... Expand
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
TLDR
Fenofibrate + simvastatin association improved lipid parameters, prothrombotic and inflammatory factors, and appeared to have a good tolerability profile over 12 months of therapy. Expand
Fibrates: therapeutic review
TLDR
The interesting results of fenofibrate on attenuation of microangiographic symptomatology potentially suggest a new recommendation for fibrate therapy, although further studies are required to validate these findings. Expand
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
  • M. Farnier
  • Medicine
  • Vascular health and risk management
  • 2008
TLDR
Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dysipidemia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 154 REFERENCES
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
TLDR
It is demonstrated that combination statin-fibrate andstatin-niacin regimens are safe and effective in managing dyslipidemias in most patients at risk for cardiovascular events who are inadequately treated with one of these agents alone. Expand
Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
TLDR
The combination of bezafibrate and simvastatin was more effective in controlling mixed hyperlipidaemia than either drug alone and did not provoke more adverse events. Expand
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
TLDR
In patients with persistent hypertriglyceridemia, combination therapy with fluvastatin and bezafibrate may be safely used to lower triglyceride and cholesterol levels more efficiently. Expand
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
TLDR
The data suggest that the statin-fibrate combinations used in the study are safe and have a favorable effect on all major coronary artery disease risk factors in patients with refractory familial combined hyperlipidemia with or without coronary arteries disease. Expand
Pharmacotherapy of hypercholesterolaemia: statins in clinical practice
The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular eventsExpand
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
TLDR
It is demonstrated that combination treatment with fenofibrate and low-dose simvastatin or pravastatin is generally safe and effective for the treatment of combined hyperlipidemia in patients with normal hepatic and renal function. Expand
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
TLDR
Statin-fibrate combination treatment for up to 3 years in a cohort of patients with coronary artery disease was not associated with serious disturbances in biochemical markers of muscle or liver function. Expand
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
TLDR
The combination of atorvastatin with micronised fenofibrate in patients with severe mixed dyslipidemia may have a favourable effect on some major coronary artery disease risk factors. Expand
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)
  • David B. Miller, J. Spence
  • Chemistry, Medicine
  • Clinical pharmacokinetics
  • 1998
TLDR
Clinically, this class of drugs appears to be most useful in lipoprotein disorders characterised by elevations of very low density lipop protein and plasma triglycerides, which are often accompanied by reductions in high densitylipoprotein (HDL) levels. Expand
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
TLDR
Patients with raised lipid concentrations were asked to participate in a study wherein the stepped NCEP treatment guidelines were used and advised caution in use of gemfibrozil and statins together due to a concern about increased risk for myopathy. Expand
...
1
2
3
4
5
...